Published in J Clin Sleep Med on August 15, 2007
Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep (2009) 2.89
Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol (2011) 1.53
Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med (2017) 1.17
Insomnia pharmacotherapy. Neurotherapeutics (2012) 1.05
Sleep in older adults: normative changes, sleep disorders, and treatment options. Clin Geriatr Med (2014) 1.01
Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem. J Clin Sleep Med (2009) 0.99
Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial. Clin Pharmacol Ther (2012) 0.95
Effect of ramelteon on middle-of-the-night balance in older adults with chronic insomnia. J Clin Sleep Med (2009) 0.92
Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection. Ther Adv Neurol Disord (2011) 0.90
New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists. Neuropsychiatr Dis Treat (2009) 0.89
Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther (2009) 0.87
Ramelteon for insomnia symptoms in a community sample of adults with generalized anxiety disorder: an open label study. J Clin Sleep Med (2009) 0.84
A review of ramelteon in the treatment of sleep disorders. Neuropsychiatr Dis Treat (2008) 0.83
Critical appraisal of ramelteon in the treatment of insomnia. Nat Sci Sleep (2010) 0.82
Melatonin and its receptors: a new class of sleep-promoting agents. J Clin Sleep Med (2007) 0.81
Ramelteon prior to a short evening nap impairs neurobehavioral performance for up to 12 hours after awakening. J Clin Sleep Med (2010) 0.80
Mood disorders, circadian rhythms, melatonin and melatonin agonists. J Cent Nerv Syst Dis (2012) 0.78
Ramelteon for the treatment of insomnia in menopausal women. Menopause Int (2009) 0.78
Effect of Placebo Conditions on Polysomnographic Parameters in Primary Insomnia: A Meta-Analysis. Sleep (2015) 0.78
Melatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value. Int J Alzheimers Dis (2010) 0.77
The effects of acute treatment with ramelteon, triazolam, and placebo on driving performance, cognitive function, and equilibrium function in healthy volunteers. Psychopharmacology (Berl) (2014) 0.77
Pharmacotherapy of insomnia with ramelteon: safety, efficacy and clinical applications. J Cent Nerv Syst Dis (2011) 0.77
Insomnia medication use and the probability of an accidental event in an older adult population. Drug Healthc Patient Saf (2010) 0.75
Pharmacological Treatment of Insomnia. P T (2015) 0.75
Therapies for insomnia and comorbid chronic obstructive pulmonary disease with a focus on ramelteon (rozerem). P T (2009) 0.75
Visual analogue scales: measurement of subjective phenomena. Nurs Res (1989) 2.45
Reliability, validity, and clinical application of the Visual Analogue Mood Scale. Psychol Med (1973) 2.31
Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction (2003) 2.06
The Benzodiazepine Withdrawal Symptom Questionnaire. J Affect Disord (1990) 1.85
Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev (2005) 1.82
Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron (1997) 1.78
Insomnia: epidemiology, characteristics, and consequences. Clin Cornerstone (2003) 1.72
Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem (2000) 1.59
Mammalian melatonin receptors: molecular biology and signal transduction. Cell Tissue Res (2002) 1.50
Insomnia in primary care patients. Sleep (1999) 1.50
Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology (2005) 1.47
An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med (2005) 1.46
A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry (1994) 1.32
Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin (2004) 1.29
Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. FASEB J (1998) 1.26
Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med (2006) 1.25
Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry (2006) 1.22
Targeted disruption of the mouse Mel(1b) melatonin receptor. Mol Cell Biol (2003) 1.21
Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group. J Clin Psychiatry (1999) 1.17
Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther (1990) 1.17
Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol (2006) 1.14
Triazolam and zolpidem: a comparison of their psychomotor, cognitive, and subjective effects in healthy volunteers. Behav Pharmacol (1997) 1.11
A meta-analysis of sleep changes associated with placebo in hypnotic clinical trials. Sleep Med (2003) 1.11
Zaleplon and triazolam in humans: acute behavioral effects and abuse potential. Psychopharmacology (Berl) (1999) 1.10
Daytime variation in performance and tiredness/sleepiness ratings in patients with insomnia, narcolepsy, sleep apnea and normal controls. J Sleep Res (2004) 1.09
Determination of the minimal clinically significant difference on a patient visual analog sleep quality scale. J Sleep Res (2003) 1.07
Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med (2004) 1.05
Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2 . Biochem Pharmacol (2001) 1.00
Sedative, memory, and performance effects of hypnotics. Psychopharmacology (Berl) (1994) 1.00
Effects on postural oscillation and memory functions of a single dose of zolpidem 5 mg, zopiclone 3.75 mg and lormetazepam 1 mg in elderly healthy subjects. A randomized, cross-over, double-blind study versus placebo. Eur J Clin Pharmacol (2003) 0.97
Melatonin--the key to the gate of sleep. Ann Med (1998) 0.87
Drugs and insomnia. NIH Consensus Development Conference. Natl Inst Health Consens Dev Conf Summ (1984) 0.78
A critical evaluation of the hypnotic efficacy of melatonin. Sleep (1997) 0.78
History of the development of sleep medicine in the United States. J Clin Sleep Med (2005) 4.22
Shift work sleep disorder: prevalence and consequences beyond that of symptomatic day workers. Sleep (2004) 3.78
Sleep loss and REM sleep loss are hyperalgesic. Sleep (2006) 3.03
Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res (2002) 2.99
Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep (2009) 2.89
Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry (2006) 2.86
The association of insomnia with anxiety disorders and depression: exploration of the direction of risk. J Psychiatr Res (2006) 2.60
Modafinil for excessive sleepiness associated with shift-work sleep disorder. N Engl J Med (2005) 2.51
Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. J Psychosom Res (2002) 2.48
A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med (2010) 2.31
Early CPAP use identifies subsequent adherence to CPAP therapy. Sleep (2007) 2.19
Sleep in lifetime posttraumatic stress disorder: a community-based polysomnographic study. Arch Gen Psychiatry (2004) 2.13
Epidemiology of DSM-IV insomnia in adolescence: lifetime prevalence, chronicity, and an emergent gender difference. Pediatrics (2006) 2.06
The association between obesity and short sleep duration: a population-based study. J Clin Sleep Med (2005) 1.87
The pediatric daytime sleepiness scale (PDSS): sleep habits and school outcomes in middle-school children. Sleep (2003) 1.86
Vulnerability to stress-related sleep disturbance and hyperarousal. Sleep (2004) 1.84
Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology (2012) 1.83
Insomnia and the performance of US workers: results from the America insomnia survey. Sleep (2011) 1.77
Sleep, sleepiness, sleep disorders and alcohol use and abuse. Sleep Med Rev (2001) 1.75
Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. J Clin Oncol (2009) 1.73
Using difficulty resuming sleep to define nocturnal awakenings. Sleep Med (2010) 1.73
Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep (2007) 1.72
Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet (2008) 1.72
Healing of critically sized femoral defects, using genetically modified mesenchymal stem cells from human adipose tissue. Tissue Eng (2005) 1.69
Laboratory and field studies of naps and caffeine as practical countermeasures for sleep-wake problems associated with night work. Sleep (2006) 1.65
Insomnia causes, consequences, and therapeutics: an overview. Depress Anxiety (2003) 1.54
Efficacy and safety of zolpidem extended release in elderly primary insomnia patients. Am J Geriatr Psychiatry (2008) 1.51
Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial. Am J Gastroenterol (2005) 1.48
An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med (2005) 1.46
Patient-reported outcomes in insomnia: development of a conceptual framework and endpoint model. Behav Sleep Med (2013) 1.43
Caffeine: sleep and daytime sleepiness. Sleep Med Rev (2007) 1.41
Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study. Mayo Clin Proc (2009) 1.38
Sleep during titration predicts continuous positive airway pressure compliance. Sleep (2003) 1.37
Sleep and pain: interaction of two vital functions. Semin Neurol (2005) 1.37
Prevalence and polysomnographic correlates of insomnia comorbid with medical disorders. Sleep (2011) 1.35
Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin (2004) 1.29
The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin (2006) 1.28
Sleep hygiene practices in a population-based sample of insomniacs. Sleep (2005) 1.26
The 10-year risk of verified motor vehicle crashes in relation to physiologic sleepiness. Sleep (2010) 1.25
Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med (2006) 1.25
Standard operation procedures for conducting the on-the-road driving test, and measurement of the standard deviation of lateral position (SDLP). Int J Gen Med (2011) 1.24
A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep (2005) 1.22
Nighttime insomnia symptoms and perceived health in the America Insomnia Survey (AIS). Sleep (2011) 1.19
Ethanol and sleep loss: a "dose" comparison of impairing effects. Sleep (2003) 1.17
The prevalence of multiple sleep-onset REM periods in a population-based sample. Sleep (2006) 1.17
Pharmacologic management of insomnia in children and adolescents: consensus statement. Pediatrics (2006) 1.16
Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration. J Clin Pharmacol (2013) 1.16
Shift work sleep disorder: burden of illness and approaches to management. Drugs (2006) 1.15
Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry (2008) 1.15
Zolpidem for insomnia. Expert Opin Pharmacother (2012) 1.14
Matrix metalloproteinases are involved in C-terminal and interglobular domain processing of cartilage aggrecan in late stage cartilage degradation. Matrix Biol (2002) 1.14
Periodic limb movements during sleep: population prevalence, clinical correlates, and racial differences. Sleep (2008) 1.13
MSLT in primary insomnia: stability and relation to nocturnal sleep. Sleep (2011) 1.13
Decision trees for identifying predictors of treatment effectiveness in clinical trials and its application to ovulation in a study of women with polycystic ovary syndrome. Hum Reprod (2010) 1.13
Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. J Clin Psychiatry (2010) 1.13
Sleep disturbance in psychiatric disorders: effects on function and quality of life in mood disorders, alcoholism, and schizophrenia. Ann Clin Psychiatry (2008) 1.12
Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol (2002) 1.09
Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial. Obstet Gynecol (2006) 1.09
Reliability and validity of the brief insomnia questionnaire in the America insomnia survey. Sleep (2010) 1.08
A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin (2007) 1.08
The associations of insomnia with costly workplace accidents and errors: results from the America Insomnia Survey. Arch Gen Psychiatry (2012) 1.07
Consequences of shiftworking on sleep duration, sleepiness, and sleep attacks. Chronobiol Int (2010) 1.07
Stress-related sleep disturbance and polysomnographic response to caffeine. Sleep Med (2006) 1.06
Circadian phase-shifting effects of repeated ramelteon administration in healthy adults. J Clin Sleep Med (2008) 1.05
Insomnia pharmacotherapy. Neurotherapeutics (2012) 1.05
Tiagabine is associated with sustained attention during sleep restriction: evidence for the value of slow-wave sleep enhancement? Sleep (2006) 1.04
Sleep reactivity and insomnia: genetic and environmental influences. Sleep (2011) 1.03
Nocturnal rapid eye movement sleep latency for identifying patients with narcolepsy/hypocretin deficiency. JAMA Neurol (2013) 1.02
Pain sensitivity in sleepy pain-free normals. Sleep (2009) 1.02
Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea. Sleep Breath (2007) 1.02
Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. J Clin Sleep Med (2007) 1.01
Neurophysiology of sleep and wakefulness: basic science and clinical implications. Curr Neuropharmacol (2008) 1.01
Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol (2011) 1.01
The venom composition of the parasitic wasp Chelonus inanitus resolved by combined expressed sequence tags analysis and proteomic approach. BMC Genomics (2010) 1.00
Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep (2011) 0.99
Pain sensitivity and recovery from mild chronic sleep loss. Sleep (2012) 0.99
Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry (2008) 0.99
A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin (2006) 0.99
Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia. Sleep (2010) 0.97
Cortical locations of maximal spindle activity: magnetoencephalography (MEG) study. J Sleep Res (2009) 0.97
'Hypnotic' prescription patterns in a large managed-care population. Sleep Med (2004) 0.97
Caffeine reversal of ethanol effects on the multiple sleep latency test, memory, and psychomotor performance. Neuropsychopharmacology (2002) 0.96
Circadian phase, sleepiness, and light exposure assessment in night workers with and without shift work disorder. Chronobiol Int (2012) 0.96
Vulnerability to insomnia: the role of familial aggregation. Sleep Med (2007) 0.96
A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep (2009) 0.96
Insomnia, comorbidity, and risk of injury among insured Americans: results from the America Insomnia Survey. Sleep (2012) 0.95
Drivers can poorly predict their own driving impairment: a comparison between measurements of subjective and objective driving quality. Psychopharmacology (Berl) (2011) 0.95
An epidemiologic study of sleep-disordered breathing symptoms among adolescents. Sleep (2006) 0.95
Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder. J Clin Psychopharmacol (2009) 0.93
An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults. Sleep Med (2004) 0.93
Identification of bracovirus particle proteins and analysis of their transcript levels at the stage of virion formation. J Gen Virol (2010) 0.93